ICD-10 Coding for Acute Kidney Injury due to Immunotherapy(N17.9, N14.1)
Complete ICD-10-CM coding and documentation guide for Acute Kidney Injury due to Immunotherapy. Includes clinical validation requirements, documentation requirements, and coding pitfalls.
Also known as:
Related ICD-10 Code Ranges
Complete code families applicable to Acute Kidney Injury due to Immunotherapy
N17-N19Primary Range
Acute kidney failure and chronic kidney disease
This range includes codes for acute kidney injury, which is the primary condition caused by immunotherapy.
Drug- and heavy metal-induced tubulointerstitial and tubular conditions
This range includes codes for drug-induced nephropathy, which may be relevant if the AKI is specifically documented as drug-induced tubulointerstitial nephritis.
Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
This range includes codes for adverse effects of drugs, which is necessary to document the causative role of immunotherapy.
Code Comparison: When to Use Each Code
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| N17.9 | Acute kidney failure, unspecified | Use when AKI is linked to immunotherapy without specific histopathological findings. |
|
| N14.1 | Nephropathy induced by other drugs and biological substances | Use if documentation explicitly states drug-induced tubulointerstitial nephritis and guidelines support its use. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information: ICD-10 code for AKI due to immunotherapy
Essential facts and insights about Acute Kidney Injury due to Immunotherapy
Primary ICD-10-CM Codes for acute kidney injury due to immunotherapy
Decision Criteria
clinical Criteria
- Documented rise in creatinine levels meeting KDIGO criteria.
coding Criteria
- Use N17.9 unless specific histopathology is documented.
documentation Criteria
- Explicit linkage of AKI to immunotherapy in clinical notes.
Applicable To
- Acute renal failure NOS
Clinical Validation Requirements
- Creatinine increase ≥1.5x baseline or ≥0.3 mg/dL within 48 hours
- Urine studies showing eosinophils or proteinuria
Code-Specific Risks
- Risk of undercoding if specific histopathology is documented but not coded.
Coding Notes
- Ensure documentation explicitly links AKI to immunotherapy.
N14.1 - Nephropathy induced by other drugs and biological substances
Use if documentation explicitly states drug-induced tubulointerstitial nephritis and guidelines support its use.
Applicable To
- Drug-induced tubulointerstitial nephritis
Excludes
- Acute kidney failure (N17.-)
Clinical Validation Requirements
- Biopsy confirming drug-induced tubulointerstitial nephritis
Coding Notes
Use only if institutional guidelines support overriding Excludes1 notes.
Ancillary Codes
Additional codes that should be used in conjunction with the main diagnosis codes when applicable.
Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5ADocumentation & Coding Risks
Avoid these common documentation and coding issues when documenting Acute Kidney Injury due to Immunotherapy to ensure proper reimbursement, maintain compliance, and reduce audit risk. These guidelines are particularly important when using ICD-10 code N17.9.
Impact
Clinical: May lead to inappropriate treatment decisions., Regulatory: Non-compliance with documentation standards., Financial: Potential for denied claims or reduced reimbursement.
Mitigation Strategy
Provide specific creatinine levels and timing., Link AKI to specific immunotherapy agent.
Impact
Reimbursement: Incorrect coding may lead to denied claims or reduced reimbursement., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data reporting.
Mitigation Strategy
Default to N17.9 unless biopsy confirms drug-induced tubulointerstitial nephritis.
Impact
Reimbursement: Potential loss of reimbursement for drug-related complications., Compliance: Failure to comply with coding standards for drug effects., Data Quality: Incomplete documentation of drug effects.
Mitigation Strategy
Always add adverse effect code for immunotherapy.
Impact
Inadequate documentation linking AKI to immunotherapy can trigger audits.
Mitigation Strategy
Ensure detailed documentation of creatinine changes and drug linkage.
Documentation errors, coding pitfalls, and audit risks are interconnected aspects of medical coding and billing. Addressing all three areas helps ensure accurate coding, optimal reimbursement, and regulatory compliance.
Frequently Asked Questions
Common questions about ICD-10 coding for Acute Kidney Injury due to Immunotherapy, with expert answers to help guide accurate code selection and documentation.
Documentation Templates for Acute Kidney Injury due to Immunotherapy
Use these documentation templates to ensure complete and accurate documentation for Acute Kidney Injury due to Immunotherapy. These templates include all required elements for proper coding and billing.
Oncology Progress Note
Specialty: OncologyRequired Elements
- Assessment of AKI stage and causation
- Creatinine levels and urine studies
- Treatment plan including drug adjustments
Example Documentation
Examples: Poor vs. Good Documentation
Poor Documentation Example
Good Documentation Example
Explanation
Need help with ICD-10 coding for Acute Kidney Injury due to Immunotherapy? Ask your questions below.